Full Breakdown
Cannabis Compounds Show Promise in Reversing Fatty Liver Disease in Mice
3/19/2026, 7:51:09 PM
Key Findings from the Research
Recent research conducted by scientists at the Hebrew University of Jerusalem has revealed that two compounds derived from the cannabis plant, cannabidiol (CBD) and cannabigerol (CBG), may reverse fatty liver disease in mice. The study indicates that these compounds can improve blood sugar control, reduce liver fat, and lower blood lipid levels in obese mice, achieving these results largely independent of classical cannabinoid receptors. Instead, CBD and CBG injections enhanced the production of phosphocreatine, a compound released by the liver that helps maintain cellular health and energy supplies. After four weeks on a high-fat diet, both compounds restored some liver functions, with CBG demonstrating particularly significant effects, including reduced body fat and increased insulin sensitivity.
Background on Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver and is distinct from alcohol-related liver disease. It is the most common chronic liver disorder globally, affecting approximately one-third of adults. The condition is not solely a liver issue; it is also a systemic metabolic disorder. Previous studies have suggested that bioactive compounds from cannabis may offer therapeutic potential for MASLD, with CBD being one of the most researched compounds.
Implications for Future Treatments
The findings from this study suggest a novel mechanism by which CBD and CBG can enhance liver function, potentially leading to new pharmacological treatments for MASLD. The authors of the study emphasize that this research is the first to demonstrate the ability of phytocannabinoids to reprogram hepatic energy buffering. While previous studies have shown creatine supplementation to have some benefits for MASLD, the current research indicates that cannabis compounds may protect the liver by promoting energy synthesis and fat clearance.
Criticism & Opposition
Despite the promising results, there are concerns regarding the regulation and purity of CBD products available on the market. Many of these products are not closely regulated, and their efficacy when consumed orally compared to direct injection remains uncertain. The study authors acknowledge the need for further research to determine whether the effects observed in mice can be replicated in humans.
Official Statements & Responses
The study highlights the urgent need for novel pharmacological agents to address the lack of approved treatments for MASLD. "Despite the increasing clinical burden of MASLD, no pharmacological treatments have been approved to date," the authors state, underscoring the significance of their findings.
What's Next
Future research will be essential to explore the mechanisms by which CBD and CBG affect liver function and to develop drug formulations that can safely and effectively deliver these compounds to patients. The study was published in the British Journal of Pharmacology, marking a significant step in understanding the therapeutic potential of cannabis-derived compounds for liver diseases.
Verbatim Quotes
- "Our findings identify a new mechanism by which CBD and CBG enhance hepatic [liver] energy and lysosomal function." — Joseph Tam, Senior Author
- "This study is the first to demonstrate that phytocannabinoids can reprogram hepatic energy buffering." — Study Authors
- "Despite the increasing clinical burden of MASLD, no pharmacological treatments have been approved to date." — Study Authors
